Revenue
Cost
Profit
| Item | Category | Value | YoY |
|---|---|---|---|
| Total revenue | revenue | 2.48B | 1.93% |
| Income before income tax (benefit) expense | profit | 377.70M | 21.37% |
| Total cost and expense | cost | 2.10B | -0.93% |
| Net income attributable to biogen inc. | profit | 319.50M | 32.85% |
| Income tax expense (benefit) | cost | 58.20M | -17.68% |
| Cost of sales, excluding amortization and impairment of acquired intangible assets | cost | 661.00M | 5.04% |
| Selling, general and administrative | cost | 607.30M | 6.08% |
| Research and development: | cost | 539.00M | 24.16% |
| Amortization and impairment of acquired intangible assets | cost | 136.50M | 22.09% |
| Collaboration profit sharing/(loss reimbursement) | cost | 74.20M | 27.71% |
| Acquired in-process research and development, upfront and milestone expense | cost | 34.00M | -83.06% |
| Business combination, contingent consideration, change in contingent consideration, liability, increase (decrease) | cost | 20.50M | 113.54% |
| Other (income) expense, net | revenue | 19.70M | -71.20% |
| Restructuring charges | cost | 7.90M | -77.62% |
| Segment | Value | YoY |
|---|---|---|
| Product | 1.75B | 1.49% |
| Revenues from anti-cd20 therapeutic programs | 419.10M | 10.81% |
| Product and Service, Other | 246.90M | -15.82% |
| LEQEMBI Collaboration | 59.50M | 80.30% |
| Item | Category | Value | YoY |
|---|---|---|---|
| Cash, cash equivalent, restricted cash, and restricted cash equivalent, continuing operation | assets | 3.38B | |
| Inventory, current | assets | 1.95B | |
| Accounts receivable, after allowance for credit loss, current | assets | 1.37B | |
| Other assets, current | assets | 1.17B | |
| Current portion of marketable securities | assets | 900.00M | |
| Total current assets | assets | 9.19B | |
| Net | assets | 9.05B | |
| Goodwill | assets | 6.49B | |
| Property, plant and equipment, net | assets | 3.02B | |
| Other assets, noncurrent | assets | 777.50M | |
| Marketable securities | assets | 465.60M | |
| Operating lease assets | assets | 251.30M | |
| Deferred tax asset | assets | 238.20M | |
| Total assets | assets | 29.48B | |
| Treasury stock, value | assets | 2.98B | |
| Accumulated other comprehensive income (loss), net of tax | liabilities | 140.20M | |
| Total equity | liabilities | 18.65B | |
| Total liabilities | liabilities | 10.83B | |
| Aggregate | liabilities | 21.77B | |
| Long-term debt | liabilities | 6.29B | |
| Total current liabilities | liabilities | 3.00B | |
| Other liabilities, noncurrent | liabilities | 787.10M | |
| Deferred income tax liabilities, net | liabilities | 483.50M | |
| Long-term operating lease liabilities | liabilities | 273.40M | |
| Retained earnings (accumulated deficit) | liabilities | 20.87B | |
| Additional paid in capital | liabilities | 896.70M | |
| Common stock, value, issued | liabilities | 100000 | |
| Total accrued expense and other | liabilities | 2.55B | |
| Accounts payable, current | liabilities | 358.50M | |
| Taxes payable, current | liabilities | 93.60M |
| Item | Value |
|---|---|
| Net income | 319.50M |
| Depreciation, depletion and amortization | 204.40M |
| Increase (decrease) in inventories | 116.20M |
| Amortization of acquired inventory step-up | 107.60M |
| Share-based payment arrangement, noncash expense | 84.00M |
| Other noncash income (expense) | 28.00M |
| Deferred income taxes | 23.60M |
| Business combination, contingent consideration, change in contingent consideration, liability, increase (decrease) | 20.50M |
| Income tax assets and liabilities | 18.40M |
| Excess and obsolescence charges related to inventory | 4.80M |
| Increase (decrease) in equity securities, fv-ni | -19.00M |
| Increase (decrease) in accounts receivable | -33.70M |
| Increase (decrease) in other operating assets and liabilities, net | -89.00M |
| Accrued expense and other current liabilities | -243.20M |
| Item | Value |
|---|---|
| Proceeds from sales and maturities of marketable securities | 625.20M |
| Proceeds from sales of strategic investments | 500000 |
| Payment for (proceeds from) other investing activity | -200000 |
| Payments to acquire in process research and development | -35.00M |
| Payments to acquire property, plant, and equipment | -51.20M |
| Payments to acquire debt securities, available-for-sale | -748.80M |
| Item | Value |
|---|---|
| Other | 11.30M |
| Payment, tax withholding, share-based payment arrangement | -55.10M |
| Item | Value |
|---|---|
| Cash and cash equivalents, beginning of period | 3.01B |
| Cash and cash equivalents, end of period | 3.38B |
Instantly decode complex 10-K and 10-Q data. Explore interactive Sankey diagrams for income and balance sheets, and intuitive waterfall charts for cash flows.
Search for a company and select a report on the left panel.
Request Stock Support